Literature DB >> 23212356

[Current therapeutic options in retinopathy of prematurity].

T U Krohne1, S Aisenbrey, F G Holz.   

Abstract

Retinopathy of prematurity is one of only few potentially blinding retinal diseases of infancy amenable to prevention of visual loss by appropriate and timely therapeutic measures. Retinal ablative therapies, such as laser coagulation eliminate the disease-causing secretion of vascular endothelial growth factor (VEGF) by the avascular peripheral retina. Blockage of VEGF activity by intravitreal administration of VEGF-inhibitory drugs has likewise proven effective in recent clinical studies. Advanced stages of the disease may require surgical intervention. Knowledge of indications and techniques of the different currently available treatment options is crucial to ensure an optimal visual outcome for the affected children.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212356     DOI: 10.1007/s00347-012-2618-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  39 in total

1.  Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity.

Authors:  M Elizabeth Hartnett; Srilakshmi Maguluri; Hilary W Thompson; Janet R McColm
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

2.  The evidence supporting the early treatment for type 1 retinopathy of prematurity needs further evaluation.

Authors:  Edward Averbukh
Journal:  Arch Ophthalmol       Date:  2005-03

Review 3.  The International Classification of Retinopathy of Prematurity revisited.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-07

4.  Screening examination of premature infants for retinopathy of prematurity.

Authors: 
Journal:  Pediatrics       Date:  2006-02       Impact factor: 7.124

5.  [Guidelines for ophthalmologic screening of premature infants].

Authors:  C Jandeck; U Kellner; B Lorenz; V Seiberth
Journal:  Ophthalmologe       Date:  2008-10       Impact factor: 1.059

6.  Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice.

Authors:  Darius M Moshfeghi; Audina M Berrocal
Journal:  Ophthalmology       Date:  2011-07       Impact factor: 12.079

7.  15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity.

Authors:  Earl A Palmer; Robert J Hardy; Velma Dobson; Dale L Phelps; Graham E Quinn; C Gail Summers; Carol P Krom; Betty Tung
Journal:  Arch Ophthalmol       Date:  2005-03

8.  A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome.

Authors:  Eugene Y J Ng; Brian P Connolly; J Arch McNamara; Carl D Regillo; James F Vander; William Tasman
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

9.  No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort.

Authors:  Philipp S Muether; Angela Kribs; Moritz Hahn; Jasmin Schumacher; Frank Eifinger; Bernd Kirchhof; Bernhard Roth; Sascha Fauser
Journal:  Br J Ophthalmol       Date:  2011-06-30       Impact factor: 4.638

10.  Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Authors:  Jian-Feng Lu; Rene Bruno; Steve Eppler; William Novotny; Bert Lum; Jacques Gaudreault
Journal:  Cancer Chemother Pharmacol       Date:  2008-01-19       Impact factor: 3.333

View more
  7 in total

1.  [Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].

Authors:  T Barth; K Hufendiek; H Helbig; I Oberacher-Velten
Journal:  Ophthalmologe       Date:  2015-06       Impact factor: 1.059

Review 2.  [Importance of investigation of fetal eyes : Supplement to fetal autopsy].

Authors:  M C Herwig-Carl; K U Loeffler; A M Müller
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 3.  Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

Review 4.  [Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020].

Authors: 
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

5.  [Retinopathy of prematurity : Current developments in therapy and epidemiology].

Authors:  T U Krohne
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

Review 6.  [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].

Authors:  T U Krohne; A Müller; P P Larsen; F G Holz
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

Review 7.  [Pharmacokinetics of intravitreally administered VEGF inhibitors].

Authors:  T U Krohne; F G Holz; C H Meyer
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.